2022-10-27 |
1 |
Complaint |
expiration
of U.S. Patent Nos. 9,044,484 and 9,421,265 (collectively, the “Asserted Patents”).
…BACKGROUND
22. U.S. Patent No. 9,044,484 (“the ’484 Patent”), entitled “Aqueous Pharmaceutical… COUNT I: INFRINGEMENT OF U.S. PATENT NO. 9,044,484
35. The Alcon Parties incorporate…claim 1 of the ’484 Patent and at
least claim 1 of the ’265 Patent. The Asserted Patents have been listed… COMPLAINT FOR PATENT INFRINGEMENT
1. This is an action for patent infringement by Alcon |
External link to document |
2024-03-01 |
119 |
Notice of Service |
Ph.D. Regarding the Invalidity of U.S. Patent Nos. 9,044,484 and 9,421,265 filed by Padagis Israel Pharmaceuticals… 27 October 2022
1:22-cv-01422
835 Patent - Abbreviated New Drug Application(ANDA)
None |
External link to document |
2022-10-27 |
3 |
ANDA Form |
Expiration of U.S. Patent No. 9,044,484: October 30, 2030. Expiration of U.S. Patent No. 9,421,265: June…
Supplemental information for patent cases involving an Abbreviated New Drug Application (ANDA) … 27 October 2022
1:22-cv-01422
835 Patent - Abbreviated New Drug Application(ANDA)
None |
External link to document |
2022-10-27 |
4 |
Patent/Trademark Report to Commissioner of Patents |
the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) US 9,044,484 B2 ; US 9,421,265… 27 October 2022
1:22-cv-01422
835 Patent - Abbreviated New Drug Application(ANDA)
None |
External link to document |
2022-11-02 |
7 |
ANDA Form |
Expiration of Patent: U.S. Patent No. 9,044,484: October 30, 2030 Date of Expiration of U.S. Patent No. 9,421,265…
Amended Supplemental information for patent cases involving an Abbreviated New Drug Application… 27 October 2022
1:22-cv-01422
835 Patent - Abbreviated New Drug Application(ANDA)
None |
External link to document |